Implication of Ceramide, Ceramide 1-Phosphate and Sphingosine 1-Phosphate in Tumorigenesis by Gangoiti, Patricia et al.
Translational Oncogenomics 2008:3 81–98 81
REVIEW
Correspondence: Antonio Gómez-Muñoz, Tel: 34-94-601 2455; Fax: 34-94-601 3500; 
E-mail: antonio.gomez@ehu.es
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Implication of Ceramide, Ceramide 1-Phosphate 
and Sphingosine 1-Phosphate in Tumorigenesis
Patricia Gangoiti
1, Maria H. Granado
1, Alicia Alonso
1,2, Félix M. Goñi
1,2 and Antonio 
Gómez-Muñoz
1
1Department of Biochemistry and Molecular Biology. Faculty of Science and Technology. University 
of the Basque Country. P.O. Box 644. 48080 - Bilbao (Spain). 
2Unidad de Biofísica (CSIC-UPV/EHU), 
Campus Universitario de Leioa. Barrio Sarriena s/n 48940 - Leioa (Spain).
Abstract: In the last two decades there has been considerable progress in our understanding of the role of sphingolipids in 
controlling signal transduction processes, particularly in the mechanisms leading to regulation of cell growth and death. 
Ceramide is a well-characterized sphingolipid metabolite and second messenger that can be produced by cancer cells in 
response to a variety of stimuli, including therapeutic drugs, leading to cell cycle arrest and apoptosis. Although this is a 
promising aspect when thinking of treating cancer, it should be borne in mind that ceramide production may not always be 
a growth inhibitory or pro-apoptotic signal. In fact, ceramide can be readily converted to sphingosine 1-phosphate (S1P) by 
the concerted actions of ceramidases and sphingosine kinases, or to ceramide 1-phosphate (C1P) by the action of ceramide 
kinase. In general, S1P and C1P have opposing effects to ceramide, acting as pro-survival or mitogenic signals in most cell 
types. This review will address our current understanding of the many roles of ceramide, S1P and C1P in the regulation of 
cell growth and survival with special emphasis to the emerging role of these molecules and their metabolizing enzymes in 
controlling tumor progression and metastasis.
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Introduction
Sphingolipid metabolites have emerged as important regulators of cell biology, and some of them are 
implicated in the control of diverse pathophysiological processes (Merrill and Jones, 1990; Hannun, 
1994, 1995, 2002; Kolesnick, 1994a, 1994b, 2002; Spiegel and Merrill, 1996; Spiegel et al. 2002, 2003, 
2006; Taha et al. 2006). Sphingomyelin (SM) is one of the most important lipids in eukaryotic cells 
because it is the precursor of bioregulatory molecules that are capable of controlling vital cell processes. 
The demonstration that acid and neutral sphingomyelinases (A-SMase, and N-SMase) were activated 
by diacylglycerol (Kolesnick et al. 1987), or vitamin D3 (Okazaki et al. 1989), suggested that SM-
derived metabolites could play relevant roles in cellular functions. These observations were reported 
independently by Hannun’s and Kolesnick’s groups who discovered the sphingomyelinase pathway 
and the physiological roles of its product, ceramide (Kolesnick, 1994; Hannun, 1994; Hannun and 
Obeid, 1995; Okazaki et al. 1990; Mathias and Kolesnick, 1993). In addition to regulating cell func-
tions, ceramide is the precursor of other bioactive lipids including sphingosine-1-phosphate (S1P) and 
ceramide-1-phosphate (C1P), both of which are important regulators of cell signaling and metabolism 
in mammalian cells (Fig. 1). Another major pathway for generation of ceramides is the de novo syn-
thesis pathway. This mechanism involves the sequential action of serine palmitoyltransferase (SPT), 
(dihydro)ceramide synthase, and (dihydro)ceramide desaturase. The latter is also the major pathway 
for production of complex sphingolipids, including SM and glycosphingolipids in eukaryotic cells. 
Recently, ceramide and some of its derivatives have been incorporated into strategies for anticancer 
therapies as discussed below and in recent reviews (Segui et al. 2006; Modrak et al. 2006; Reynolds 
et al. 2004). In normal tissues, the major component of ceramide is sphingenine, while ceramides from 
tumor cells contain, in addition to sphingenine, signiﬁ  cant amounts of sphinganine (Rylova et al. 1998). 
Ceramide metabolism can also generate molecules with antagonistic effects. In particular, C1P and S1P 
can counteract many of the effects of ceramides, and conversely ceramides have opposing effects to 
C1P and S1P (Gomez-Muñoz, 1998, 2004, 2006). This is an important aspect because ceramide, C1P 82
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and S1P can be rapidly interconverted and this may 
determine the overall signal that is ﬁ  nally transmit-
ted in cells. Therefore, the balance between the 
levels of these metabolites seems to be crucial for 
cell and tissue homeostasis. Switching this balance 
towards accumulation of S1P and C1P versus 
ceramide may result in abnormal stimulation of 
cell proliferation and/or inhibition of apoptosis 
leading to tumor formation. Obviously, the activity 
of the enzymes that are involved in the regulation 
of S1P, C1P and ceramide metabolism must be 
efﬁ  ciently coordinated to ensure appropriate intra-
cellular concentrations of these metabolites and 
normal cell physiology.
Many reports have shown that S1P is mitogenic 
and can inhibit cell death in numerous cell types 
(Spiegel et al. 1993, 1996, 2000a,b, 2002, 2003). 
Another major metabolite of ceramide is ceramide-
1-phosphate (C1P), which can be formed through 
direct phosphorylation of ceramide by ceramide 
kinase. There are only a few studies suggesting 
that C1P is an important regulator of cell homeostasis 
(reviewed in Gómez-Muñoz, 2004, 2006). 
Increasing evidence indicates that C1P can regulate 
cell proliferation and that it is a potent inhibitor of 
apoptosis (Gómez-Muñoz et al. 1995, 1997, 2004, 
2005; Mitra et al. 2007). In addition, Chalfant and 
co-workers have demonstrated that C1P is a posi-
tive regulator of inﬂ  ammatory responses (reviewed 
in Chalfant and Spiegel, 2005; Lamour and 
Chalfant, 2005). Other reports have implicated C1P 
in the control of phagocytosis (Hinkovska-Gal-
cheva et al. 1998, 2005). In the present article we 
review recent developments related to the control 
of cell homeostasis by ceramide, S1P and C1P with 
special emphasis to the role of these metabolites 
in tumorigenesis and metastasis.
Regulation of Cell Homeostasis 
by Sphingolipids
Tissue homeostasis in higher organisms is deter-
mined by a network of complex processes that are 
tightly regulated. These include systems to balance 
Figure 1. Biological roles of some sphingolipids involved tumorigenesis and metastasis. A variety of stimuli including cytokines, ionizing 
radiation, chemotherapeutic agents, or stress can induce ceramide formation in cells. There are two major pathways for ceramide genera-
tion: the de novo synthesis pathway and the hydrolysis of sphingomyelinase (SM) by sphingomyelinases (SMases). In general, ceramides 
mediate pro-apoptotic and anti- proliferative responses whereas sphingosine 1-phosphate (S1P) and ceramide 1-phosphate (C1P) are 
mitogenic and antiapoptotic for most cell types. The mechanism whereby C1P blocks apoptosis involves direct inhibition of acid SMase. 
Formation of glycosylceramide (GlcCer) confers resistance to a variety of drugs used in cancer therapy.
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cell proliferation and cell death to ensure proper 
development of the organism. Any alteration of 
this balance can potentially lead to disease, includ-
ing autoimmune diseases, and cancer (Zhang and 
Xu, 2002; Vaux and Korsmeyer, 1999; Thompson, 
1995). Therefore, identiﬁ  cation of effector mole-
cules that are involved in the regulation of cell 
proliferation and death is crucial for developing 
therapeutical strategies for prevention or treatment 
of these illnesses.
As mentioned above, SMases (E.C. 3.1.4.12) 
are key enzymes in sphingolipid metabolism 
because they can generate ceramide, a death signal 
for most cells, or C1P and S1P, which have growth 
factor properties. SMases are a class of enzymes 
that belong to the phosphodiesterase superfamily. 
Mammalian cells utilize three distinct forms of 
SMases, which can be discriminated in vitro by 
their optima pH: acidic, neutral and alkaline sphin-
gomyelinases. Both, acidic SMase (A-SMase) and 
neutral SMase (N-SMase) are known to be involved 
in signal transduction in mammalian cells, whereas 
alkaline SMase is mainly responsible for digestion 
of dietary SM in the intestine (reviewed in Gómez-
Muñoz, 2006b). Nonetheless, a potential implica-
tion of alkaline SMase in cell signaling processes 
has recently been suggested by Hertervig and 
co-workers (2003) who have demonstrated that 
alkaline SMase inhibits proliferation without 
inducing apoptosis in HT-29 human colon carci-
noma cells. In addition, DNA sequencing identiﬁ  ed 
a deletion of exon 4 in alkaline SMase of HT-29 
cells, resulting in relatively low enzyme activity 
in these cells compared to normal cells (Wu et al. 
2004). A reduction of alkaline SMase activity was 
also found in the stools of colorectal cancer patients 
compared to normal individuals (reviewed by 
Duan, 2006). For detailed information on the enzy-
mology and compartmentalization of SMases, the 
reader is referred to previous reviews (Goñi and 
Alonso, 2002, 2006; Cremesti et al. 2002; Kole-
snick et al. 2002). Concerning neutral and acidic 
SMases, there is evidence suggesting that stimula-
tion of these enzyme activities is an important 
factor in cell cycle arrest and apoptosis (Kolesnick 
and Golde, 1994; Hannun, 1994; Hannun and 
Obeid, 2002; Hundal et al. 2003; Gomez-Munoz 
et al. 2003, 2004). Stimulation of SMase activity 
is the predominant pathway for ceramide genera-
tion in response to chemotherapy (cysplatin, 
doxorubicin, paclitaxel, and histone deacetylase 
inhibitors). Among all of the SMases, the best 
characterized enzyme is the acidic isoform 
A-SMase. In humans, mutation of the SMPD1 gene 
results in deﬁ  ciency of A-SMase activity leading 
to Niemann-Pick disease types A and B, a highly 
lethal illness. Although A-SMase was the ﬁ  rst 
SMase to be puriﬁ  ed and cloned (Schuchman et al. 
1991), regulation of its activity has only recently 
begun to be elucidated. Recent work by Hannun’s 
group has shown that A-SMase is regulated by 
phosphorylation through activation of PKCδ 
(Zeidan and Hannun, 2007), and more recently we 
have demonstrated that A-SMase can be regulated 
by the action of Gi proteins (Wang et al. 2007). 
Speciﬁ  cally, the bacterial toxin of Bordetella per-
tussis (pertussis toxin: PTX), which works through 
ADP-ribosylation of Gi proteins causing their 
inactivation, potently inhibited A-SMase and 
ceramide formation. By contrast, mastoparan, a 
well-known Gi protein activator, stimulated 
A-SMase and ceramide generation leading to 
apoptosis. Of importance, A-SMase can be directly 
inhibited by C1P, an action that involves this phos-
phosphingolipid in the inhibition of apoptosis and 
promotion of cell survival (see below).
Ceramide levels can also be controlled by SM 
synthase, the enzyme that catalyzes the transfer of 
phosphocholine from phosphatidylcholine to 
ceramide producing diacylglycerol and SM. In fact, 
this enzyme has been implicated in cell regulation 
and transformation through its ability to modulate 
the levels of ceramide and diacylglycerol, two 
essential bioactive lipids, and it may account, at 
least in part, for some of the effects previously 
attributed to phosphatidylcholine-speciﬁ  c phos-
pholipase C (Luberto and Hannun, 1998). In addi-
tion, sphingosylphosphorylcholine (SPC), the 
N-deacylated form of SM, is produced under 
physiological and pathological conditions, and has 
been shown to be a positive regulator of wound 
healing, angiogenesis and cell proliferation, as well 
as causing inhibition of cell growth (Gomez-
Munoz, 1998; Xu, 2002). SPC can be metabolized 
to sphingosine by neutral SMases (Miura et al. 
2004), or to S1P by autotaxin (Clair et al. 2003). 
Therefore, SM deacylase may also be an important 
enzyme in controlling cell homeostasis.
Ceramides and the Suppression 
of Tumor Progression
The direct product of SM, ceramide (N-acylsphingosine), 
is among the least polar, more hydrophobic lipids 84
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in cell membranes. Its solubility in water is 
negligible; thus, free ceramide cannot exist in solu-
tion in biological ﬂ  uids or in the cytosol. A number 
of studies have been carried out to try to understand 
the behaviour of ceramides as they occur in lipid 
bilayers, which essentially consist of a phospho-
lipid matrix. In systems at equilibrium, long chain 
(natural) ceramides have three main effects on 
phospholipid bilayers: a) they can increase the 
order of the acyl chains in bilayers, b) they give 
rise to in-plane phase separation of ceramide-rich 
and—poor domains, and c) they facilitate the tran-
sition from bilayer to non-bilayer structures 
(Kolesnick et al. 2000). Because of their high 
hydrophobicity, ceramides can exert their primary 
actions at the membrane level; they can only act 
on membrane-related proteins, that is, proteins 
permanently or transiently linked to membranes. 
In principle, this may occur in two different ways: 
1) on proteins lacking speciﬁ  c ceramide binding 
sites, ceramide may act by inducing (localized) 
changes in the physical properties of the membrane 
bilayer, for example, increase in lipid chain order, 
which can in turn modify enzyme activities. Inte-
gral, or intrinsic proteins, are particularly sensitive 
to changes in bilayer order and/or ﬂ  uidity (Watts, 
1993). Membrane proteins may also respond to the 
tendency of the membranes to form non-bilayer 
phases, due to the presence of certain lipids that 
favor the lamellar-to-nonlamellar transition, for 
example diacylglycerol and ceramide (Epand, 
1985; Kinnunen, 1996). Additional ceramide-
induced changes in bilayer properties that could 
inﬂ  uence the activity of proteins not necessarily 
containing ceramide-binding sites, are the lateral 
segregation of ceramide into certain membrane 
domains (lipid rafts or platforms), and the 
ceramide-induced facilitation of protein-protein 
contacts; 2) ceramides may bind to speciﬁ  c sites 
in the target protein, thereby modulating enzyme 
action. This mechanism may operate not only on 
proteins that are permanently bound to membranes, 
but also protein molecules transiently recruited to 
the bilayer where ceramides are located (see 
Kolesnick et al. 2000; Goñi and Alonso, 2006 for 
further details). There are two groups of proteins 
that are known to contain ceramide-binding sites: 
a) proteins that are transiently bound to mem-
branes, such as ceramide-activated protein kinase 
(CAPK), some protein kinase C (PKC) isoforms, 
or c-Raf-1; b) proteins without known membrane-
binding capacity, such as ceramide-activated protein 
phosphatase 1 (CAPP1) or ceramide-activated 
protein phosphatase 2 (CAPP2A) CAPPs are 
among the best characterized ceramide targets. 
Treatment with exogenous ceramide or TNFα, a 
ceramide-generating agonist, caused dephosphor-
ylation of c-Jun in A431 cells. Pre-treatment of 
these cells with okadaic acid completely blocked 
the effects of exogenous ceramide and TNFα on 
c-Jun, suggesting a PP2A form of CAPP (Reyes 
et al. 1996). Increased mitochondrial PP2A activ-
ity and speciﬁ  c dephosphorylation of mitochon-
drial Bcl-2 in response to ceramide has also been 
demonstrated (Ruvolo et al. 1999; Ruvolo et al. 
1998). Another described substrate for CAPP is 
PKB (Akt). This kinase mediates many anti-
apoptotic biological actions (Sato et al. 2000) and 
plays key roles in insulin action and in mitogenic 
signaling (Hajduch et al. 2001). PKB has been 
demonstrated to be dephosphorylated by PP2A 
prior to activation of caspase 9 and Bad (Basu et al. 
1998; Cardone et al. 1998) and has been suggested 
to be a necessary event in turning off a key anti-
apoptotic mechanism. Several lines of evidence 
have indicated the ability of ceramide to induce 
dephosphorylation of PKB with concomitant loss 
of function/activity (Reviewed by Pettus et al. 
2002), and pre-treatment with okadaic acid 
revealed a role for PP2A in regulating the activity 
of this enzyme (Hajduch et al. 2001; Cazzolli et al. 
2001; Schmitz-Peiffer et al. 1999; Salinas et al. 
2000). More recently, activation of CAPP has been 
negatively implicated in the regulation of PKC 
autophosphorylation, leading to inactivation of this 
enzyme activity. The speciﬁ  c isoforms that were 
sensitive to dephosphorylation by CAPP were 
PKC α and βII (Kitatani et al. 2007). In particular, 
activation of these PKC isoforms leads to stimula-
tion of phospholipase D (PLD), an enzyme that 
produces promitogenic phosphatidic acid (PA) 
(reviewed by Exton, 1999). Indeed, we previously 
demonstrated that short-chain ceramides are potent 
inhibitors of PLD in different cell types (Gomez-
Muñoz et al. 1994, 1995, 2000, 2001; Pérez-Andres 
et al. 2002), an action that supports the antiprolif-
erative effect of ceramides.
An important aspect of ceramide action con-
cerns its transport from the ER, where it is synthe-
sized de novo, to the Golgi apparatus, the primary 
site of SM and glycosphingolipid synthesis. In this 
concern, Hanada and co-workers demonstrated the 
existence of a speciﬁ  c protein that is crucial for 
SM biosynthesis and acts as a ceramide transfer 85
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protein (CERT) in a non-vesicular manner. This 
protein has two suitable domains for the transport 
of ceramide: one domain that recognizes ceramide 
and mediates its intermembrane transfer, termed 
the START domain, and a phosphatidylinositol 
binding domain (PH domain) with selectivity 
towards phosphatidylinositol-4-phosphate, a lipid 
that is enriched in the Golgi and that could serve 
as the site for ceramide delivery by CERT (Hanada 
et al. 2003).
Ceramides have been shown to be mediators of 
cellular stress. There are many agents that can 
induce accumulation of ceramides within cells; 
these include cytokines (TNFα, interleukins, 
FasL), UV or ionizing radiation, heat shock, 
hypoxia, or chemotherapeutic drugs such as dau-
norubicin, vincristine, etoposide, fenretidine, 
cysplatin, among others. The biological activity of 
ceramides is inﬂ  uenced by different structural ele-
ments. In particular, insertion of a trans 4–5 double 
bond in the molecule, an action that is catalyzed 
by (dihydro)ceramide desaturase, seems to be 
crucial for ceramide activity; also, ceramides can 
be more or less active depending on the length of 
the N-acyl chain that is linked to the sphingosine 
backbone (Goñi and Alonso, 2006; Modrak et al. 
2006). Similarly, sphingomyelins with differing 
N-acyl chain lengths are capable of providing vary-
ing degrees of chemosensitization (Modrak et al. 
2006). The kinetics of ceramide formation in 
response to different stimuli are complex and vari-
able; this responses range from seconds to hours, 
and the same stimulus can generate different 
responses in different cell types (Hannun, 1996). 
Unexpectedly, it was observed that ceramide levels 
were higher in ras or tyrosine kinase ( fps) trans-
formed ﬁ  broblasts compared to non-transformed 
cells (Martin et al. 1997), and similar results were 
obtained in human head and neck squamous cell 
carcinomas (HNSCC) compared to noncancerous 
tissues (Koybasi et al. 2004); however, when indi-
vidual ceramide species were examined the results 
demonstrated that only C18:0-ceramide was lower 
in HNSCC tumor tissues as compared to their 
noncancerous counterparts (206 versus 392 pmol/mg 
protein, respectively) whereas the levels of all the 
other ceramide species were generally higher in 
HNSCC tumors than in their controls. It was con-
cluded that C18:0-ceramide plays a role in the 
pathogenesis/progression of the HNSCC (Koybasi 
et al. 2004). It was also reported that ceramides are 
inversely associated with malignant progression 
of human astrocytomas, which supports the rational 
for the potential beneﬁ  ts of ceramide-based che-
motherapy (Riboni et al. 2002b).
Molecular targets of ceramides
The mechanisms whereby ceramides exert their 
biological actions include modulation of diverse 
signal transduction pathways and key regulatory 
enzymes. CAPK is a member of a family of pro-
line-directed serine/threonine kinases (Liu et al. 
1994), whose activity can be enhanced by treat-
ment of intact cells with short-chain ceramide 
analogs, bacterial sphingomyelinases, TNFα, or 
interleukin 1-beta (IL-1β) (Zhang and Kolesnick 
1995). CAPK was identiﬁ  ed as the kinase suppres-
sor of Ras (KSR), and was associated with phos-
phorylation and activation of Raf-1 and the 
subsequent activation of MAPK (Yao et al. 1995; 
Zhang et al. 1997). As previously mentioned 
another well-deﬁ  ned target for ceramide action is 
CAPP (CAPP1 and CAPP2A) (Dobrowsky and 
Hannun, 1992; Kolesnick, 2002). Some speciﬁ  c 
substrates of CAPP have already been identiﬁ  ed; 
these include c-Jun (Reyes et al. 1996), Bcl-2 
(Ruvolo et al. 1999), protein kinase B (PKB) (Zhou 
et al. 1998), PKC-α (Lee et al. 1996), retinoblas-
toma protein (Rb) (Plummer et al. 2005) and SR 
proteins (Chalfant et al. 2001). Ceramides also can 
directly activate the protein kinase C isoform PKC-
ζ (Lozano et al. 1994; Muller et al. 1995), leading 
to stimulation of stress-activated protein kinases 
(SAPK) also known as Jun nuclear kinases (JNKs). 
Activation of this pathway leads to multiple effects, 
including alternative splicing through activation 
of hnRNP A1 and inhibition of protein synthesis 
via the RAX-PKR (double-stranded RNA-depen-
dent protein kinase/elIF1-alpha pathway (Modrack 
et al. 2006). Thus, the protease cathepsin D is 
activated by ceramides and participates in the 
activation of executionary caspase 3 after translo-
cation from the lisosomes (De Stefanis et al. 2002). 
Also, inhibition of the nuclear transcription factor 
NF-κB by ceramides has been observed in a vari-
ety of cell systems (reviewed by Gómez-Muñoz, 
1998, 2004, 2006). Lastly, another important target 
of ceramide is phospholipase D (PLD). It was ﬁ  rst 
demonstrated that ceramides are potent inhibitors 
of PLD activity in rat ﬁ  broblasts that were chal-
lenged with different agonists including mitogenic 
agents such as lysophosphatidic acid (LPA), S1P, 
thrombin, or serum (Gómez-Muñoz et al. 1994, 1995). 86
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Ceramides were also able to block PLD activation 
by oxidized low density lipoproteins (Gómez-
Muñoz et al. 2000), which were shown to stimulate 
growth of murine macrophages (Hundal et al. 
2003). The inhibitory effect of ceramide on PLD 
is likely to be caused by direct interaction of the 
sphingolipid with enzymes or factors that directly 
activate PLD, such as PKCα or the small G pro-
teins ADP ribosylation factor (ARF) and Rho. 
Therefore, in addition to inducing apoptosis, 
ceramides are negative regulators of signalling 
pathways that are associated with the stimulation 
of cell proliferation (Gómez-Muñoz, 1998).
As mentioned above, formation of ceramide is 
equally relevant because it is the precursor of 
important bioactive sphingolipids that can also 
regulate cellular functions (Fig. 1). Hence, stimu-
lation of ceramidases results in generation of 
sphingosine, which was first described as an 
inhibitor of protein kinase C (PKC) (Hannun et al. 
1986) and can also inhibit phosphatidate phospho-
hydrolase (PAP) activities (Gómez-Muñoz et al. 
1992). These actions may inﬂ  uence cell homeo-
stasis because diacylglycerol, the product of PAP 
activity, and PKC are positive regulators of cell 
proliferation. Sphingosine, in turn, can be phos-
phorylated by the action of sphingosine kinases to 
generate S1P, which is a potent mitogenic agent 
and can also inhibit apoptosis in many cell types 
(Wu et al. 1995; Spiegel and Merrill, 1996; Spiegel 
et al. 1993, 1996; Spiegel and Milstein, 2002, 2003; 
Hait et al. 2006; Taha et al. 2006). Thus, cerami-
dases might be important enzymes for tumor pro-
motion. In this connection, human acid ceramidase 
has been shown to be overexpressed, although not 
mutated, in 42% prostate cancer specimens and in 
three prostate cancer cell lines (Seelan et al. 2000) 
and inhibition of ceramidase activity with aromatic 
ceramide analogues showed effective anticancer 
activity in melanoma and colon cancer cells 
(Raisova et al. 2002; Selzner et al. 2001).
Therapeutic possibilities of ceramide 
metabolism
Chemotherapy-mediated increases of ceramide 
levels in tumor cells may be due to stimulation of 
the de novo synthesis pathway, to an increased 
SMase activity, or to disruption of ceramide 
catabolism. Therefore, manipulation of the path-
ways responsible for ceramide formation and its 
metabolism may be effective targets for cancer 
therapy. Well-defined targets in the de novo 
synthesis pathway are serinepalmitoyl transferase 
(SPT), of which there are two isoforms, SPT1 and 
SPT2, and ceramide synthase activities. Induction 
of these enzymes would lead to an increase in 
ceramide levels. In particular, the synthetic anti-
cancer drug fenretinide increases the activity of 
both SPT and ceramide synthase, leading to growth 
inhibition of neuroblastoma, melanoma, and other 
tumors (reviewed by Ribatti et al. 2003). Paclitaxel, 
or etoposide can also elevate ceramide levels 
through stimulation of the de novo pathway, and 
anthracylines like doxorubicin can stimulate both 
the SMase and the de novo synthesis pathways. 
Paradoxically, SPT expression has been shown to 
be enhanced in proliferating ﬁ  broblasts, some 
transformed cell lines and some human tumors 
(Batheja et al. 2003). In the latter report both SPT1 
and SPT2 appeared to be associated with the 
nucleus in actively proliferating cells, whereas the 
two SPT isoforms were much less abundant in 
nuclei of quiescent cells. The function of SPT1 and 
SPT2 associating with the nucleus in de-differen-
tiated, proliferating cells is unknown at present, 
but it might be possible that nuclear localization 
of SPT is implicated in sphingolipid nuclear sign-
aling. The contradictory observation that SPT can 
be implicated in promoting apoptosis as well as 
cell proliferation could be explained by the differ-
ent levels of expression of ceramide kinase, and/or 
SK in different cell types. Cells with low levels of 
ceramide kinase or SK activities will have difﬁ  cul-
ties to convert SPT-derived proapoptotic ceramide 
into antiapoptotic or promitogenic C1P or S1P, 
whereas cells with high levels of these kinases will 
rapidly form C1P and S1P at the expense of cera-
mides. Therefore, another possibility for improving 
cancer therapy would be to prevent the metabolism 
of ceramide to S1P or C1P, as these metabolites 
have opposing effects to ceramide. In this context, 
drugs like the inhibitor B13, which potently blocks 
ceramidase activity, have been shown to enhance 
tumor cell apoptosis (Selzner et al. 2001). Also, 
saﬁ  ngol (L-threo-dihydrosphingosine), a potent 
sphingosine kinase (SK) inhibitor, is commonly 
used in cancer therapy to avoid formation of S1P, 
and the recently identiﬁ  ed inhibitor of ceramide 
kinase, F-1209A, can be used to inhibit C1P gen-
eration (Kim et al. 2005).
Ceramidase-derived sphingosine may also be 
acylated by ceramide synthase to form a stereo-
chemically variant L-threo ceramide that cannot 87
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be glucosylated by glycosylceramide synthase 
(GCS) to generate glycosylceramide (reviewed by 
Reynolds et al. 2004) and this has been shown to 
synergistically enhance tumor cell killing by the 
ceramide-generating retinoid fenretidine (Maurer 
et al. 2000). The latter compound, also known as 
N-(4-hydroxyphenyl) retinamide, is cytotoxic for 
human leukemia cells through generation of 
ceramides by both SMase activation and stimula-
tion of the de novo pathway (Morales et al. 2007). 
Robust ceramide generation through activation of 
the de novo pathway was also observed after 
administration of the natural phytochemical cur-
cumin to human colon cancer cells, and this led to 
cell death by apoptosis (Moussavi et al. 2006). 
Improvement of cancer therapy could also be 
achieved by preventing glycosphingolipid forma-
tion after administration of ceramide-producing 
drugs. Glycosylceramide (GlcCer), lactosylce-
ramide, and gangliosides play essential roles in cell 
development, cell death, and tumor progression. 
Radioresistant melanoma cells rich in gangliosides 
can be made radiosensitive by exposure to fumo-
nisin B1, which blocks ganglioside biosynthesis at 
the level of ceramide synthase. Conversely, adding 
bovine brain ganglioside M1 to radiosensitive 
melanoma cells can confer radioresistance. Several 
reports have shown that over-expression of gluco-
sylceramide synthase (GCS), or P-glycoprotein 
transporters induce drug-resistance. This suggests 
that shunting ceramide to a glycosylated form may 
decrease the cytotoxic effects of drug-producing 
ceramides, thus inhibition of this step might poten-
tiate toxicity of chemotherapeutic agents thereby 
improving cancer cell killing. A comprehensive 
review by Gouaze-Andersson and Cabot, (2006), 
discusses the role of glycosphingolipids in drug 
resistance toward cancer treatment.
Sphingosine-1-Phosphate 
and Ceramide 1-Phosphate Promote 
Cell Growth and Survival—Possible 
Role in Tumorigenesis
Stimulation of ceramidases generates sphingosine, 
which can control the activity of key enzymes 
involved in the regulation of metabolic or cell 
signaling pathways, i.e. inhibition of the Mg
2+ 
dependent form of phosphatidate phosphohydro-
lase (PAP) (Jamal et al. 1991; Gómez-Muñoz et al. 
1992), inhibition of PKC (Hannun et al. 1986), 
activation of PLD (Natarajan et al. 1994), or 
stimulation of diacylglycerol kinase (Sakane et al. 
1989; Yamada et al. 1993). However, many of the 
effects of sphingosine are known to be mediated 
through its conversion to S1P (Desai et al. 1992). 
In addition to being produced intracellularly, many 
cells can secrete important amounts of S1P under 
certain circumstances. S1P is present in serum at 
relatively high concentrations (up to 1 µM), where 
it is bound to albumin. It is mainly produced and 
stored in red blood cells and platelets, and it can 
be released to the extracellular milieu upon cell 
activation (Pappu et al. 2007). Extracellular S1P 
can also be secreted by other cell types such as 
mast cells and monocytes (Watterson et al. 2003). 
The mechanisms that regulate S1P secretion are 
poorly understood at the present time. The intracel-
lular levels of S1P are under strict regulation by 
the enzymes that control its biosynthesis and deg-
radation. Sphingosine kinase (SK) catalyzes the 
ATP-dependent phosphorylation of sphingosine to 
generate S1P, whereas degradation of S1P can be 
mediated by two different pathways: a) the revers-
ible dephosphorylation to sphingosine by different 
phosphatases, and b) the irreversible degradation 
to hexadecenal and ethanolamine phosphate by 
speciﬁ  c lyase activity (Merrill and Jones, 1990). 
SK activity has been demonstrated in most mam-
malian tissues, yeast, and plants. In mammals, two 
distinct SK isozymes (termed SK1 and SK2) have 
been characterized. These two isoforms have dif-
ferent kinetic properties and are differently distrib-
uted among tissues suggesting that they regulate 
different cellular functions. In particular, SK1 has 
been shown to promote cell survival, proliferation, 
and tumor cell growth (Johnson et al. 2002; Nava 
et al. 2002; Taha et al. 2004, 2006; Kohno et al. 
2005), whereas SK2 has been described as a puta-
tive BH3-only protein that is associated with the 
induction of apoptosis, and cell cycle arrest (Liu 
et al. 2003; Maceyka et al. 2005). Stimulation of 
SK activity has been observed in response to a 
variety of agonists including TNF-α, nerve growth 
factor (NGF), vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDFG), 
epidermal growth factor (EGF), or basic ﬁ  broblast 
growth factor (reviewed by Saba and Hla, 2004). 
The mechanisms whereby SK activity is stimulated 
have not been fully described, but it is known that 
SK1 is phosphorylated by protein kinase C (PKC) 
upon treatment of endothelial cells with VEGF 
(Rosenfeldt et al. 2001) and that SK1 gene expres-
sion is mediated by PKC- and ERK-dependent 88
Gangoiti et al
Translational Oncogenomics 2008:3 
signal transduction pathways (Spiegel and Milstein, 
2003).
The degradation of S1P can be catalyzed by 
different phosphatases, and by S1P lyase (Brindley 
and Waggoner, 1996; Giussani et al. 2006; Saba 
and Hla, 2004; Merrill and Jones, 1990). There are 
two isoforms of S1P phosphatase (SPP), which are 
designated SPP1 and SPP2. Both of these phos-
phatases localize to the endoplasmic reticulum 
(Saba and Hla, 2004) where they dephosphorylate 
S1P speciﬁ  cally. In addition, S1P can be dephos-
phorylated by a Mg
2+-independent and N-
ethylmaleimide insensitive phosphatidate 
phosphohydrolase (PAP-2) that resides in the 
plasma membrane of cells (Waggoner et al. 1996). 
PAP-2 belongs to a family of enzymes that were 
renamed lipid phosphate phosphatases (LPPs) 
(Brindley and Waggoner, 1996). This new nomen-
clature was adopted because this enzyme can also 
catalyze the dephosphorylation of various other 
phospholipids besides phosphatidic acid (PA), 
mainly lysoPA, C1P, and S1P. SPPs differ from 
LPPs in that SPPs are highly speciﬁ  c toward long 
chain sphingoid base phosphates; also the enzy-
mological properties of these two families of 
phosphatases are different (Le Stunff, 2002; Ogawa 
et al. 2003). As for the role of mammalian SPPs it 
was found that dephosphorylation of S1P stimu-
lated the de novo synthesis of ceramide (Le Stunff 
et al. 2004). This observation is consistent with the 
stimulation of PAP-2 by C2-ceramide that we pre-
viously reported (Gómez-Muñoz et al. 1994), and 
with the ability of this cell-permeable ceramide to 
stimulate the metabolism of S1P and the production 
of intracellular ceramides (Posse de Chaves et al. 
1997; Gómez-Muñoz et al. 1995; Ogretmen et al. 
2002). More recently, SPP1 was shown to also 
regulate the ER-to-Golgi trafﬁ  cking of ceramide 
(Giussani et al. 2006), and SPP2 has been demon-
strated to be induced during inflammatory 
responses in different cell types (neutrophils, endo-
thelial cells, and epithelial cells (Mechtcheriakova 
et al. 2007). Increases in SPP2 activity occurred at 
late time points after treatment with various ago-
nists. TNF-α, Lipopolysaccharide (LPS), or the 
phorbol ester PMA increased mRNA levels of 
SPP2, after 6-8 h treatment, whereas none of these 
agonists or the growth factor EGF caused any 
signiﬁ  cant changes in SPP2 activity at early time 
points (Mechtcheriakova et al. 2007). The latter 
authors also demonstrated that the SPP2 promoter 
has two nuclear factor-kappa B (NF-κB) binding 
sites. Speciﬁ  cally, Rel A is the NF-κB subunit that 
is critical for SPP2 induction of transcription. The 
importance of SPP1 as a key regulatory enzyme in 
cell homeostasis has been recently highlighted by 
the discovery that overexpression of this enzyme 
in human embryonic kidney cells suppresses motil-
ity towards epidermal growth factor (EGF) by 
reducing S1P accumulation in response to EGF. In 
agreement with this, downregulation of SPP1 
increases the intracellular levels of S1P, and 
facilitates its secretion to the extracellular milieu. 
This action results in activation of a heterotrimeric 
Gi protein-coupled S1P receptor, possibly by an 
autocrine pathway (Le Stunff et al. 2004), and has 
important implications on cell viability (Johnson 
et al. 2003). It can be concluded that dephosphor-
ylation of S1P can be catalyzed by both speciﬁ  c 
SPPs, and LPPs, and that these actions may have 
profound effects in the control of cell growth and 
survival, as well as in inﬂ  ammation.
The irreversible degradation of S1P is catalyzed 
by S1P lyase through cleavage of the C2-3 carbon 
bond of S1P. This generates palmitaldehyde and 
ethanolamine phosphate (Merrill and Jones, 1990). 
Like SPPs, S1P lyase is found in the ER (Saba and 
Hla, 2004) where most of the essential enzymes 
for sphingolipid biosynthesis are localized. It has 
been shown that S1P lyase stimulates the de novo 
synthesis of ceramides, and that induces apoptosis 
through stimulation of the intrinsic apoptotic path-
way that is associated to cytochrome c release from 
mitochondria (Reiss et al. 2004). It was postulated 
that S1P lyase can regulate mammalian cell sur-
vival by controlling the intracellular levels of S1P 
and ceramides (Reiss et al. 2004; Saba and Hla, 
2004). Also, it was reported that S1P lyase is impli-
cated in the regulation of important biological 
functions in different organisms. For instance, in 
C. elegans, Dictyostelium, or Drosophila, this 
enzyme activity plays an important role in embryo-
genesis, reproduction, survival, or movement (Saba 
and Hla, 2004). More recently, S1P lyase has been 
shown to potentiate apoptosis via p53 and p38-
dependent pathways, and that it is downregulated 
in colorectal carcinomas (Oskouian et al. 2006). 
These observations led to the prediction that loss of 
S1P lyase expression could contribute to tumor cell 
survival. In fact, deletions of the 10q21 chromosomal 
region where the human S1P lyase locus resides 
have been demonstrated in a variety of cancers 
(Ichimura et al. 1998; Petersen et al. 2000; Petersen 
et al. 1998). Basal intracellular concentrations 89
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of S1P is in the range of low pmols per mg of 
protein (about 2.3 pmol/mg protein in Chinese 
Hamster Ovary cells ) (Tani et al. 2005) and this 
amount is to be higher in tumor cells lacking S1P 
lyase.
Another putative tumor-promoting sphingolipid 
is C1P. The existence of C1P was ﬁ  rst reported by 
Dressler and Kolesnick in human leukemia (HL-
60) cells (Dressler and Kolesnick, 1990). Ceramide 
kinase (CERK), the enzyme responsible for C1P 
formation in cells, was ﬁ  rst identiﬁ  ed in brain 
synaptic vesicles by Bajjalieh and co-workers 
(1989), and then found in human leukemia HL-60 
cells (Kolesnick and Hemer, 1990). This enzyme 
was conﬁ  ned to the microsomal membrane frac-
tion, and it phosphorylated ceramide in the pres-
ence of physiological calcium concentrations. Of 
importance, human CERK has been recently 
cloned by Sugiura and co-workers (Sugiura et al. 
2002). With regard to substrate speciﬁ  city, it was 
reported that phosphorylation of ceramide by 
CERK is stereospeciﬁ  c (Wijesinghe et al. 2005). 
The latter report also showed that a minimum of a 
12-carbon acyl chain was required for normal 
CERK activity. The importance of CERK in cell 
signaling was highlighted using speciﬁ  c siRNA to 
downregulate this enzyme activity in A549 lung 
adenocarcinoma cells. This treatment dramatically 
inhibited arachidonic acid release and prostaglan-
din E2 (PGE2) production in response to ATP, the 
calcium ionophore A23187 and interleukin 1-β 
(Chalfant and Spiegel, 2005; Pettus et al. 2003). It 
has been known for a long time that there is a strong 
association between chronic inﬂ  ammation and 
cancer. The fact that C1P is a strong activator of 
cPLA2 places CERK as a new potential therapeu-
tic target for cancer treatment and/or prevention.
Recently, a human ceramide kinase-like 
(CERKL) enzyme was identiﬁ  ed in retina (Tuson 
et al. 2004) and subsequently cloned (Bornancin 
et al. 2005). However, this enzyme was unable to 
phosphorylate ceramide, or other related lipids, 
under conditions commonly used to measure 
CERK activity, and therefore its role in cell biology 
is unclear.
It was previously reported that C1P can be 
formed in neutrophils upon addition of exogenous 
cell-permeable [
3H]N-hexanoylsphingosine (C6-
ceramide) to the cells (Rile et al. 2003). Riboni and 
co-workers (2002a) demonstrated that C1P could 
be generated in cerebellar granule cells both from 
SM-derived ceramide and through the recycling 
of sphingosine produced by ganglioside catabolism. 
C1P can be also generated by the action of inter-
leukin 1β on A549 lung adenocarcinoma cells 
(Pettus et al. 2003), and plays an important role in 
inﬂ  ammation (Chalfant and Spiegel, 2005; Pettus 
et al. 2003, 2004, 2005; Subramanian et al. 2005). 
We found that C1P is present in normal bone mar-
row-derived macrophages (Gómez-Muñoz et al. 
2004), and that its levels are substantially decreased 
in apoptotic macrophages. This observation sug-
gested that C1P may play an important role in cell 
survival (Gómez-Muñoz, 2004b, 2006). The iden-
tiﬁ  cation of C1P phosphatase in rat brain (Shinghal 
et al. 1993) and hepatocytes (Boudker and Futer-
man, 1993) together with the existence of CERK 
suggested that ceramide and C1P are interconvert-
ible in cells. C1P phosphatase is enriched in brain 
synaptosomes and liver plasma membrane frac-
tions, and appeared to be distinct from the phos-
phatase that hydrolyzes phosphatidic acid (PA), PA 
phosphohydrolase (PAP). Nonetheless, C1P can 
also be converted to ceramide by the action of a 
PAP activity that is speciﬁ  cally located in the 
plasma membrane of cells (Waggoner et al. 1996). 
The latter enzyme belongs to a family of at least 
three mammalian lipid phosphate phosphatases 
(LPPs) (Brindley and Waggoner, 1998). LPPs have 
recently been shown to regulate cell survival by 
controlling the levels of intracellular PA and S1P 
pools (Long et al. 2005) and to also regulate leu-
kocyte inﬁ  ltration and airway inﬂ  ammation (Zhao 
et al. 2005). Dephosphorylation of C1P might be 
a way of terminating its biological effects, and the 
resulting formation of ceramide could potentially 
be detrimental for cells. In any case, controlling 
the levels of ceramide and C1P by the coordinated 
action of CERK and C1P phosphatases, may be of 
crucial importance for the metabolic or signaling 
pathways that are regulated by these two sphingo-
lipids.
Biologic effects of sphingosine-1-
phosphate and ceramide 1-phosphate
The tumor microenvironment is rich in lipid 
metabolites, of which one of the most relevant is 
S1P. Receptors for bioactive lipids including S1P 
are involved in aberrant cell proliferation in a wide 
range of cancer cells. S1P was ﬁ  rst described as a 
mitogen for cultured ﬁ  broblasts (Zhang et al. 
1990) and was subsequently implicated in the 
regulation of cell migration, survival, invasion, 90
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and angiogenesis (Ancellin et al. 2002; Merrill 
et al. 2002; Payne et al. 2002; Donati and Bruni, 
2006), processes that are all essential for tumor 
progression. Most pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF), pro-
mote the translocation of SK1 to the plasma 
membrane, thereby promoting the local accumula-
tion of S1P. In turn, S1P stimulates its G-protein 
coupled receptors (GPCRs S1P1-5) in several 
tumor and stromal cells. Among them, S1PR1, 
previously known as EDG-2, is highly expressed 
in endothelial cells. Stimulation of this receptor 
promotes the secretion of VEGF by endothelial 
cells, and inhibition of S1P with a blocking anti-
body prevents the release of IL6, IL8 and VEGF 
by tumor cells, suggesting that S1P production 
and S1P1 activation are required to elicit an angio-
genic response (Dorsam and Gutking, 2007). Just 
as cancer cells co-opt chemokine and bioactive 
lipid networks to invade surrounding tissue, reach 
the vascular and lymphatic circulation and migrate 
and invade their target tissues, they can also 
manipulate these networks and their GPCRs to 
attract endothelial cells and instruct them to invade 
the tumor mass, thereby forming new vessels to 
provide nutrients and oxygen.
C1P was also found to be mitogenic as it stim-
ulated DNA synthesis and cell division in rat 
ﬁ  broblasts (Gómez-Muñoz et al. 1995). The ﬁ  rst 
studies were performed using synthetic short-chain 
C1Ps (C2-C1P and C8-C1P) that were enzymically 
synthesized using C2- and C8-ceramides as sub-
strates. Of interest, C1P was also able to reverse 
the morphological changes that were induced in 
rat ﬁ  broblasts after prolonged serum deprivation, 
a condition that induces apoptosis in those cells 
(Gómez-Muñoz, 1998), suggesting a role of C1P 
in the promotion of cell survival. This new action 
of C1P was later confirmed in bone marrow-
derived macrophages that were incubated in the 
absence of growth factors (see below).
In rat ﬁ  broblasts, the mitogenic effects of S1P 
and C1P could be blocked by ceramides, possibly 
through a mechanism involving stimulation of S1P 
and C1P degradation by LPP activity (Gómez-
Muñoz et al. 1995a,b). S1P and C1P have been 
demonstrated to counteract the pro-apoptotic effect 
of ceramide (Olivera and Spiegel, 1993; Gómez-
Muñoz et al. 2004, respectively). Therefore, 
ceramides and S1P or C1P play antagonistic roles 
in cell signaling. These ﬁ  ndings, together with the 
observation that S1P regulates ceramide synthesis, 
support the idea of the sphingolipid “rheostat 
model”, in which the balance between S1P and 
ceramides is crucial for cell fate decisions (Spiegel 
and Milstein, 2003). Many of the effects of S1P 
are elicited through its interaction with speciﬁ  c Gi 
protein-coupled receptors (S1P1-5) that are ubiqui-
tously expressed and regulate numerous down-
stream signals. These aspects of S1P signaling have 
been recently discussed in several comprehensive 
reviews (Watterson, 2003; Saba and Hla, 2004; 
Spiegel and Milstein, 2003; Payne et al. 2002; 
Donati and Bruni, 2006), therefore they will not 
be addressed in detail here. Also, S1P has been 
shown to be generated intracellularly by the action 
of certain growth factors, and serum (Olivera and 
Spiegel, 1993; Coroneos et al. 1995). In particular, 
PDGF, or serum stimulate SK activity and the 
production of S1P in Swiss 3T3 ﬁ  broblasts (Rani 
et al. 1997). However, no direct intracellular targets 
of S1P have so far been conclusively characterized. 
It has been suggested that S1P may play a role in 
the regulation of cell cycle progression, as PDGF 
can induce translocation of SK into the nuclear 
envelope and increase nuclear-associated SK activ-
ity (Kleuser et al. 2001). Activation of SK by PDGF 
leads to mitogen-activated protein kinase (MAPK) 
extracellular regulated kinases 1/2 (ERK 1/2) 
stimulation, and S1P inhibits c-Jun N-terminal 
kinase (JNK) activation (Cuvillier et al. 1996). The 
latter ﬁ  ndings are relevant because the extent of 
activation of ERK versus JNK is an important 
aspect in the regulation of apoptosis (Xia et al. 
1995). S1P has been shown to act intracellularly 
as a second messenger to regulate cell proliferation, 
suppression of apoptosis, and cell survival (Payne 
et al. 2002; Spiegel and Milstein, 2002; Taha et al. 
2006; Donati and Bruni, 2006). The biological 
actions elicited by S1P involve activation of 
diverse signaling pathways. For example, effects 
of S1P on cytoskeletal rearrangement and cell 
motility are mediated by the small GTPases Rac 
and Rho, whereas stimulation of cell proliferation 
and cell survival by S1P involves intracellular Ca
2+ 
mobilization and activation of MAPK, phospholi-
pase D, and transcription factors such as AP-1 
(Payne et al. 2002; Spiegel and Milstein, 2002). 
Therefore, S1P can function both as ﬁ  rst and sec-
ond messenger, and these actions may differentially 
affect speciﬁ  c intracellular targets or signaling 
pathways (Vann et al. 2002).
Two recent reports showed that S1P and C1P 
increased cell survival in bone marrow-derived 91
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macrophages that were incubated in the absence 
of M-CSF, a condition that induces apoptosis in 
these cells (Gómez-Muñoz et al. 2003). It was 
demonstrated that both of these phosphosphingo-
lipids inhibited caspase 9 and 3 activation, as well 
as DNA fragmentation, indicating that they were 
blocking apoptosis. In addition, both S1P and C1P 
prevented the accumulation of ceramides that 
occurs in apoptotic macrophages incubated in the 
absence of M-CSF. Both acid and neutral SMase 
activities were upregulated by M-CSF deprivation, 
but nearly all of the SMase activity was attributable 
to the acidic form of the enzyme. A key observation 
in those studies was that S1P or C1P completely 
inhibited the activation of A-SMase in intact cells, 
which resulted in blockade of ceramide accumula-
tion. It is not clear whether or not these effects of 
S1P and C1P are receptor-mediated events. How-
ever, experiments performed in the presence of 
pertussis toxin failed to reverse the inhibitory effect 
of these metabolites on A-SMase activation. In 
addition, A-SMase activation was independent of 
cAMP, as treatment with the adenylyl cyclase 
activating agent forskolin, at concentrations shown 
to elevate cAMP, did not alter A-SMase activity in 
the macrophages. These data are in agreement with 
previous studies suggesting that the cytoprotective 
effects of S1P are receptor-independent events 
(Spiegel and Milstein, 2003). Another key observa-
tion was that C1P blocked the activity of A-SMase 
in cell homogenates suggesting that inhibition of 
this enzyme occurs by direct physical interaction 
with C1P. Consequently, C1P was considered to 
be a selective inhibitor of A-SMase. Inhibition of 
this enzyme has now been demonstrated to be a 
major mechanism whereby C1P promotes cell 
survival (Gómez-Muñoz et al. 2004). This observa-
tion also suggested that inhibition of A-SMase by 
C1P is not mediated through receptor interaction. 
Interestingly and contrary to C1P, the inhibitory 
effect of S1P did not involve direct interaction with 
A-SMase. Activation of A-SMase also plays a key 
role in pulmonary infections as it facilitates inter-
nalization of bacteria into lung epithelial cells 
(Gulbins and Kolesnick, 2003). Therefore, inhibi-
tion of A-SMase by C1P or S1P could be an impor-
tant mechanism to reduce or prevent infection of 
mammalian cells.
An important pathway that is a positive regula-
tor of cell survival is the phosphatidylinositol 3-
kinase (PI3-K)/protein kinase B (PKB) pathway. 
In mammalian cells, PKB (also known as Akt) is 
activated downstream of PI3-K when cells are 
stimulated by growth factors, insulin, or certain 
G-protein-coupled receptor agonists. Once acti-
vated, PKB can promote a variety of cellular 
responses, including cell growth, inhibition of 
apoptosis, cell proliferation, or cell migration. 
Many of the functions that are regulated by PKB 
involve binding of 14-3-3 proteins to the sites of 
PKB phosphorylation. Concerning apoptosis, 14-
3-3 proteins have been shown to bind to YAP65, 
and transcription factors of the FOXO family. In 
addition, PKB can also positively regulate G1/S 
cell-cycle progression through different mecha-
nisms, including phosphorylation of the CDK 
inhibitor p27 (Kip1), and 14-3-3 proteins have been 
shown to bind these PKB-phosphorylated sites 
(reviewed by Mackintosh 2004).
We previously demonstrated that activation of 
the PI3-K/PKB pathway, but not MAPK, was 
required for the anti-apoptotic effect of S1P and 
C1P in BMDM (Gómez-Muñoz et al. 2003, 2005). 
PI3-K activation was demonstrated by immuno-
precipitation of the enzyme from whole cell lysates 
and assayed in vitro using 
32P-phosphatidylinositol. 
An in vivo approach provided evidence of phos-
phatidylinositol (3,4,5)-trisphosphate (PIP3) for-
mation in intact cells that were prelabeled with 
32P-orthophosphate. PIP3 is a major product of 
PI3-K activity, and has recently been shown to 
directly inhibit A-SMase (Testai et al. 2004). It is 
possible that PI3-K activation might enhance the 
inhibitory effect of C1P or S1P on ASMase through 
generation of PIP3. Whether C1P and PIP3 bind 
to the same or different domains of A-SMase 
remains to be determined. The expression of anti-
apoptotic Bcl-XL, which is regulated by PI3-K, 
was also decreased by M-CSF withdrawal, and S1P 
or C1P restored Bcl-XL to normal levels. It was 
concluded that the PI3-K/PKB signaling cascade 
is a positive regulator of S1P- or C1P mediated cell 
survival, and that inhibition of A-SMase activity 
and the subsequent decrease in ceramide levels by 
S1P or C1P is an important factor for maintaining 
PKB activation and macrophage survival. In fact 
C2-ceramide, but not the inactive form dihydro- 
C2-ceramide, blocked S1P- or C1P-induced cell 
survival, thereby emphasizing the importance for 
cells to maintain an appropriate balance between 
the intracellular levels of these metabolites. The 
metabolic or signaling pathways that are regulated 
by C1P are not well characterized, but unlike S1P, 
C1P does not affect PLD, MAPK (ERK 1/2), 92
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adenylyl cyclase, Ca
2+ mobilization, or the 
expression of the early genes c-fos or c-myc in rat 
or mouse ﬁ  broblasts (Gómez-Muñoz, 1995, 1997). 
Nonetheless, a slight induction of ERK phos-
phorylation was demonstrated in human osteoblas-
tic cells stimulated with short-chain C1P (Carpio 
et al. 1999) and we have preliminary evidence 
suggesting that natural C1P stimulates macrophage 
proliferation through ERK1/2 activation (P. Gangoiti 
et al. unpublished work). It is obvious from the 
above observations that the activity of the enzymes 
involved in ceramide, C1P and S1P metabolism 
must be strictly regulated so that cells can keep 
appropriate levels of pro- apoptotic versus 
anti-apoptotic metabolites. Any alteration in the 
balance between ceramides, C1P and S1P could 
potentially result in development of illnesses 
including cancer.
Targeting sphingosine 1-phosphate 
and ceramide 1-phosphate formation 
as therapeutic possibilities
Regulation of S1P and C1P metabolism provides 
a new therapeutic possibility for cancer treatment. 
The blockage of S1P and C1P formation will lead 
to inhibition of proliferation, as well as the induc-
tion of apoptosis in cancer cells. Recently identiﬁ  ed 
SK1 inhibitors have been shown to inhibit cancer 
cell proliferation and tumor growth in vitro and in 
vivo in animal models (French et al. 2006; Ségui 
et al. 2006). However, speciﬁ  c inhibition of SK1 
can be complicated, because SK1 shares with SK2 
two large conserved regions, which feature about 
80% similarity at the protein level, as well as ﬁ  ve 
short sequence stretches, designated C1–C5. 
Another possibility is preventing interaction of S1P 
with its receptors. There are some novel S1P1 and 
S1P3 antagonists (Davis et al. 2005) that could 
inhibit cancer cell growth. However, there is evi-
dence suggesting that some of the effects of S1P 
are receptor independent (Kohno et al. 2005). In 
addition, targeting S1P receptors might be compli-
cated because of the existence of multiple isoforms 
with different responses (Ancellin et al. 1999; 
Spiegel and Milstien, 2000; Ségui et al. 2006).
A novel approach to cancer treatment uses a 
monoclonal antibody that binds S1P with high 
afﬁ  nity and speciﬁ  city. The anti-S1P mAb substan-
tially reduced tumor progression and in some cases 
it eliminated measurable tumors in murine 
xenograft and allograft models. The anti-S1P mAb 
inhibited tumor associated angiogenesis, 
S1P- induced proliferation, and the ability of S1P 
to protect tumor cells from apoptosis in several 
tumor cell lines (Visentin et al. 2006).
In 1858, Rudolf Virchow suggested that cancers 
frequently occured at sites of chronic inﬂ  ammation. 
In the light of the pro-survival and pro-inﬂ  amma-
tory functions of C1P, CERK, the enzyme respon-
sible for C1P formation, might be an important 
target for the development of novel anti-cancer 
drugs. In this regard, non-steroidal anti-inﬂ  amma-
tory drugs (NSAIDs) are being used to treat several 
types of cancer. Overexpression of cPLA2 has been 
observed in several human cancers and cell lines 
such as NSCLC (non small lung squamous carci-
nomas) (Heasley et al. 1997) or human colorectal 
adenocarcinomas (Osterstrom et al. 2002). Down-
regulation of this enzyme by deleting the Pla2g4 
locus can cause a reduction in the size of these 
tumors (Hong et al. 2001); furthermore, blockage 
of cPLA2 activation through inhibition of C1P 
formation might have similar effects as knocking 
down cPLA2, thereby causing a reduction of ara-
chidonic acid release and prostanoid formation. 
Otherwise, although some SK inhibitors are known 
to cause partial inhibition of CERK when used at 
high concentrations, effective and speciﬁ  c inhibi-
tors of CERK have not been reported until recently 
(Kim et al. 2005). The latter authors have devel-
oped some analogs of the SK inhibitor F-12509A 
and found an oleﬁ  n isomer with promising applica-
tions as it inhibits CERK without affecting SK or 
diacylglycerol kinase activities.
Concluding Remarks
Many sphingolipids, in particular ceramides and 
their derivatives C1P and S1P, are bioeffector 
molecules that control important cellular processes, 
some of which are directly implicated in carcino-
genesis. Inﬂ  ammation is one of the processes that 
have been associated to tumor formation for many 
years. The inﬂ  ammatory response is a complex 
process that involves hundreds of genes; hence, 
there are many genes in the inﬂ  ammatory pathways 
that might contribute to the development of cancer. 
Some of these pathways, as well as pathways 
involved in the regulation of cell proliferation and 
apoptosis are regulated by sphingolipids. There-
fore, sphingolipid metabolism may be an appropri-
ate area for identiﬁ  cation of therapeutic targets. 
Cancer chemotherapy has classically focused on 93
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targeting DNA or key proteins that are involved in 
DNA synthesis and repair with the aim of causing 
lethal damage to malignant cells with tolerable 
toxicity to normal tissues. In the last few years, 
cancer drug development has also been based on 
new observations related to sphingolipid metabo-
lism aiming at designing more selective approaches 
for inducing tumor cell death or cytostasis. Manip-
ulation of ceramide, S1P and C1P levels, or the 
activity of the enzymes that control their metabo-
lism might provide a unique opportunity for cancer 
treatment or prevention.
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